BullMarket.com Updates Outlooks on Generic Drugmaker Stocks

Tools

PRINCETON, N.J., March 30 /PRNewswire/ -- BullMarket.com (http://www.bullmarket.com), an online investment newsletter focused on long-term growth and income-generating stocks, has provided subscribers with coverage of several generic drugmakers, including Teva Pharmaceuticals (Nasdaq: TEVA), Mylan (Nasdaq: MYL), Watson Pharmaceuticals (NYSE: WPI), and Perrigo (Nasdaq: PRGO).

All paid and trial subscribers to BullMarket.com can now receive immediate access to the newsletter's exclusive daily reports. As a subscriber, you'll also gain access to our Recommended List of stocks, which was up 40% in 2009 and also outperformed the S&P by 15% in 2008.

Start your 14-day free trial today:

https://www.bullmarket.com/subscribe/pr/?refer=BMR705P

In its daily report, BullMarket.com wrote: "Shares of Israel-based Teva have been on an almost steady rise since the market upheaval of November 2008. The stock largely shrugged off the March 2009 bottom and has been climbing fairly steadily, with most retracements followed by new surges."

BullMarket.com looked at the following topics, among others:

-- Why has Teva's stock been on such a tear? Can its strong run continue?

-- What should help drive Mylan's growth in the next few years?

-- What catalyst should Watson see in the second half of next year?

-- Why does Perrigo's deal for PBM Holdings look like a good one?

About BullMarket.com:

Launched in 1997, BullMarket.com has a strong track record of creating wealth for its subscribers by providing sound, long-term investing advice. The BullMarket.com Recommended List includes about 50 companies across all major industries, including Financials, Healthcare, Energy, Technology, and Retail, among others. BullMarket.com is one of the oldest continuously published investment newsletters online, and its Recommended List has consistently outperformed the major market indices.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Contact:

Indie Research Advisors, LLC

Marcie Martin, +1-888-278-5515

SOURCE Indie Research Advisors, LLC